IL17A and myeloid sarcoma: Recent advancements in understanding the biology of Th17- and IL-17-producing γδ T cell and their implication in autoimmune diseases, including MS, could suggest new therapeutic targets for MS by targeting Th17- and IL-17-producing γδ T cells populations.